{
    "2020-01-06": [
        [
            {
                "time": "",
                "original_text": "“瘦身”计划已正式开启！从“买买买”到“归核化”，上市药企这几年经历了什么？",
                "features": {
                    "keywords": [
                        "瘦身计划",
                        "买买买",
                        "归核化",
                        "上市药企"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "中生制药跌逾3% 主动卖盘58%暂连跌2日",
                "features": {
                    "keywords": [
                        "中生制药",
                        "跌逾3%",
                        "主动卖盘",
                        "连跌2日"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "安信国际 | 2020医药行业：集采带来不确定性，创新仍是发展主线",
                "features": {
                    "keywords": [
                        "安信国际",
                        "医药行业",
                        "集采",
                        "不确定性",
                        "创新"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【权益变动】复星医药(02196-HK)获复星国际控股增持46万股",
                "features": {
                    "keywords": [
                        "复星医药",
                        "复星国际",
                        "增持",
                        "46万股"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "智通港股通持股解析|1月3日",
                "features": {
                    "keywords": [
                        "智通港股通",
                        "持股解析"
                    ],
                    "sentiment_score": 0.0,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}